Hill-Rom (NYSE:HRC) had its price objective lifted by KeyCorp from $114.00 to $125.00 in a research report report published on Monday morning, BenzingaRatingsTable reports. KeyCorp currently has an overweight rating on the medical technology company’s stock. KeyCorp also issued estimates for Hill-Rom’s FY2021 earnings at $6.25 EPS.
HRC has been the topic of several other reports. Zacks Investment Research raised Hill-Rom from a hold rating to a buy rating and set a $103.00 target price on the stock in a research report on Thursday, June 6th. Barclays increased their target price on Hill-Rom from $103.00 to $108.00 and gave the stock an equal weight rating in a research report on Monday, April 15th. Finally, ValuEngine lowered Hill-Rom from a buy rating to a hold rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Hill-Rom has an average rating of Buy and an average target price of $112.43.
Shares of HRC opened at $104.10 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.51 and a debt-to-equity ratio of 1.12. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of 19.93, a P/E/G ratio of 1.73 and a beta of 0.90. The business has a fifty day moving average price of $105.23. Hill-Rom has a twelve month low of $81.82 and a twelve month high of $109.18.
Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, August 2nd. The medical technology company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.02. The business had revenue of $726.80 million for the quarter, compared to analyst estimates of $718.08 million. Hill-Rom had a return on equity of 21.26% and a net margin of 7.45%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted $1.15 EPS. On average, equities research analysts forecast that Hill-Rom will post 5.05 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Friday, September 20th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.81%. The ex-dividend date is Thursday, September 19th. Hill-Rom’s dividend payout ratio (DPR) is presently 17.68%.
A number of large investors have recently added to or reduced their stakes in the business. Litman Gregory Asset Management LLC acquired a new position in Hill-Rom in the second quarter worth about $26,000. Hanseatic Management Services Inc. acquired a new position in Hill-Rom in the first quarter worth about $30,000. Sageworth Trust Co acquired a new position in Hill-Rom in the first quarter worth about $32,000. Tortoise Investment Management LLC acquired a new position in Hill-Rom in the second quarter worth about $31,000. Finally, TRUE Private Wealth Advisors acquired a new position in Hill-Rom in the second quarter worth about $38,000. 81.52% of the stock is currently owned by institutional investors.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.